

Corporate Presentation


Nasdaq CPIX

Safe Harbor Statement

This presentation contains forward-looking statements concerning our product development, our technology, our intellectual property, our financial condition and our plans for research and development programs that involve risks, uncertainties and assumptions. These statements are based on the current estimates and assumptions of the management of Cumberland Pharmaceuticals as of the date of this presentation and are subject to uncertainty and changes in circumstances. Given these uncertainties, you should not place undue reliance upon these forward-looking statements. Such forward-looking statements are subject to risks, uncertainties, assumptions and other factors that may cause the actual results of Cumberland Pharmaceuticals to be materially different from those reflected in such forward-looking statements.

Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, among others, those set forth under the headings "Risk factors" and "Management's discussion and analysis of financial condition and results of operations" in our Form 10-K and Form 10-Q Reports on file with the SEC. The Company does not undertake any obligation to release publicly any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. All statements contained in this presentation are made only as of the date of this presentation. More information can be found at www.cumberlandpharma.com.

Nation's Health Care Capital



Company Overview



Innovative biopharmaceutical company

Phase II candidates in development with study results milestones

Proven record of successful **product development**

Mission & Strategy


Mission: Working together to provide unique products that improve the quality of patient care

Strategy: We are developing *innovative biopharmaceutical brands*

Ifetroban Overview

- Cumberland's first **new chemical entity**
- A **potent, selective** antagonist of thromboxane receptor
- Discovered and initially developed by Bristol-Myers Squibb
- **Safety well-established** in 30 clinical studies with **over 1,400 subjects**
- Collaborating with **Vanderbilt, Harvard, Scripps** and other academic centers
- Successfully manufactured **both IV** and **oral formulations**

Ifetroban Development Pipeline



Duchenne Muscular Dystrophy (DMD)


- **A rare, fatal, neuromuscular disease** with the progressive loss of muscle resulting in deterioration of the skeleton, heart and lungs
- Cumberland is investigating ifetroban for the treatment of **cardiomyopathy** that is associated with DMD
- **Preclinical data** demonstrates ifetroban could prevent cardiac fibrosis and improve cardiac function – published **Journal American Heart Association**
- The **FDA** has awarded over $1 million in **Orphan Drug Grant** funding
- **Orphan Drug** and **Rare Pediatric Disease** Designations approved
- **Phase II study** completed with **breakthrough results** announced
- **Fast Track** Designation also approved!

Systemic Sclerosis (SSc)

- Debilitating, **chronic autoimmune disease** causing thickening of the skin and fibrosis of internal organs
- **Highest death rate** of any rheumatic condition
- Average **survival** is approximately **11 years** from diagnosis
- **Women** more commonly affected; also occurs in **children**
- No FDA approved treatment for this **unmet medical need**
- **Phase II study** enrollment completed
- **Top line study results** to be reported next

Fibroban® in IPF

- Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) are a group of disorders that causes irreversible scarring (fibrosis) of lung tissue that leads to lung function decline and early mortality
- Idiopathic **Pulmonary Fibrosis** (IPF) is the most common form of PF-ILDs
- **Orphan disease**
- IND cleared and **Phase II study** is well underway





CET®
Cumberland *Emerging* Technologies

CET®
Cumberland *Emerging* Technologies

- **Joint initiative** to build **long term pipeline**
- Collaborating with **Academic Research** Partners
- Building **portfolio** of innovative **biopharmaceutical candidates**
- Supporting product development through **grant initiatives**
- Managing Nashville's **Life Science Center**
- Houses **Cumberland's formulation** and **testing laboratories**

Cumberland Moving Forward



Proven **development** capabilities



Phase II products in development with study results milestones



Valuation gap given assets, infrastructure and pipeline



NASDAQ: CPIX